

1 **Findings in Travel-related Thrombosis and COVID-19 Related Cardiac Biomarker Data: Combination of**  
2 **Novel Review Strategy and Meta-analysis Method Discovered Twenty-eight Days Cycles of Thrombosis**  
3 **and Latent Subgroup Patterns**

4  
5 **Authors' names**

6 Keiichiro Kimoto, M.Sc.\* (0000-0002-5123-6123), Munekazu Yamakuchi, M.D., Ph.D. (0000-0003-2181-7194),  
7 Kazunori Takenouchi, M.D., Ph.D. (0000-0003-1946-457X), Teruto Hashiguchi, M.D., Ph.D. (0000-0003-4820-  
8 8268)

9  
10 **Address for each author and positions**

11 Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and  
12 Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan, Keiichiro Kimoto, research student of  
13 laboratory and vascular medicine (present affiliation: External Advisor for Data Strategy Research Institute,  
14 Yokohama, Japan), Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School  
15 of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan, Munekazu Yamakuchi,  
16 associate professor of laboratory and vascular medicine, Department of Laboratory and Vascular Medicine,  
17 Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-  
18 8520, Japan, Kazunori Takenouchi, assistant professor of laboratory and vascular medicine, Department of  
19 Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-  
20 35-1 Sakuragaoka, Kagoshima 890-8520, Japan, Teruto Hashiguchi, professor of laboratory and vascular  
21 medicine.

22  
23 **Corresponding author information**

24 \*Corresponding author: Keiichiro Kimoto (0000-0002-5123-6123)

25 E-mail: [k1974142@kadai.jp](mailto:k1974142@kadai.jp)

26 Department of Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and  
27 Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.

28 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**  
29 Phone: /Fax: +81-99-275-5437/+81-99-275-2629

30 **Author contributions**

31 Keiichiro Kimoto takes responsibility for this research, making study concepts, data analysis, interpretation of  
32 analysis results, and manuscript drafting. Dr. Yamakuchi contributed to interpreting analysis results, manuscript  
33 drafting, supervision, and administrative role. Dr. Takenouchi contributed to the supervision. Dr. Hashiguchi  
34 contributed to the study concept, interpretation of analysis results, manuscript drafting, supervision, and  
35 administrative role.

36  
37 **Copyright**

38 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors,  
39 an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing  
40 Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGJL products  
41 and sublicences such use and exploit all subsidiary rights, as set out in our licence.

42  
43 **Competing interest statement**

44 Munekazu Yamakuchi, Kazunori Takenouchi, and Teruto Hashiguchi have completed the Unified  
45 Competing Interest form and declare: no support from any organization for the submitted work; no financial  
46 relationships with any organizations that might have an interest in the submitted work in the previous three  
47 years, no other relationships or activities that could appear to have influenced the submitted work. Keiichiro  
48 Kimoto has been in charge of external advisor for the Data Strategy Research Institute but received no financial  
49 support for this study.

50  
51 **Classification:** Research article

52 **Keywords**

53 Traveler's thrombosis, cardiovascular biomarker, COVID-19, Oral Contraceptives (OC), and Hormone  
54 Replacement Therapy (HRT)

55  
56 This file includes Abstract, Summary boxes, Main Text, Figures 1 to 7, and Table 1. Also, this article  
57 has supporting information that contains supporting figures, tables, method details, and supporting discussions.

58  
59

60

## 61 **Abstract**

### 62 **Backgrounds**

63 Traveler's thrombosis is well-known even among non-professionals as "economy class syndrome." However,  
64 controversial discussions have remained. Clark et al. mentioned no solid evidence in their article "*Long-haul  
65 travel and venous thrombosis: What is the evidence?*" (1). Also, the status of recent COVID-19-related  
66 thrombosis research seemed like that of the traveler's thrombosis. We hypothesized there might be something  
67 overlooked behind those strange situations.

68

### 69 **Methods**

70 Since ordinary review methods (e.g., systematic review or meta-analysis) had already been conducted (2-7), we  
71 focused on reviewing a "previously published" "chart." Also, we developed a novel "review method" for the  
72 meta-regression analysis result. We applied those to some previously published and well-known data.

73

### 74 **Results**

75 We newly found an approximately 28 days cycle of thrombosis onset over several weeks after travel in a figure  
76 (Cannegieter et al., *PLoS Med.* 2006, in the top 25% of all research scored by Altmetric) (8). Also, we found an  
77 eighteen-day cycle of thrombosis onset in another chart (Kelman et al., *BMJ.* 2003, in the top 5% of research)  
78 (9). In COVID-19, we newly extracted subgroup patterns in a scatterplot (Troponin T and NT-proBNP) that  
79 applied simple linear regression analysis (Guo et al. *JAMA Cardiol.* 2020, top 5% research) (10). Also, these  
80 subgroups have already appeared in the cardiomyopathy study (Budnik et al., *Int J Cardiol.* 2016) (11).

81

### 82 **Conclusions**

83 There has been a widespread belief that in-flight environments cause thrombosis. Also, the phenomenon of the  
84 onset of thrombosis after over a few weeks to two months since the travel has been explained, such as the  
85 development of blood clots occurring on a cabin, but the dislodge of a thrombus occurs after the travel (12).  
86 However, from cyclic patterns of thrombosis onset, it is more reasonable to explain that the "travel" and "high-  
87 risk period of thrombosis with Oral Contraceptives (OC) use (within three months from starting OC)" coincided  
88 with the travel (e.g., honeymoon and starting birth control OC). The influence of the in-flight environment may  
89 be less than we had previously thought. Although simple linear regression analysis has been used in studies of

90 cardiovascular biomarkers, including the case of COVID-19, there seems to be a complex scatterplot structure  
91 that is unsuitable for simple linear fitting. Considering our findings, in a literature review, a pattern on a chart  
92 should be given more paying attention.

93

#### 94 **Summary boxes**

##### 95 **What is already known on this topic**

96 Strange controversies have remained in thrombosis-related fields (traveler's and COVID-19-related thrombosis).  
97 Traveler's thrombosis sometimes occurs over two months after leaving the risky in-flight environment. This  
98 phenomenon has been explained that the thrombus is formed in a cabin but dislodged after (12). Oral  
99 contraceptives (OC) were recognized as aggravating factors (13). COVID-19, although this is the first time  
100 humans have faced SARS-Cov-2, there has been a long research history on infectious-associated thrombosis.

101

##### 102 **What this study adds**

103 We hypothesized something might be overlooked and focused on reviewing a "previously published" "chart."  
104 We found thrombosis onset cycles. These findings may imply thrombosis after travel is caused by overlapping  
105 the travel period and the initial period of taking OC, which is the high-risk period for thrombosis. In COVID-19  
106 cardiovascular biomarker studies, there seems to be a complex scatterplot structure that is unsuitable for usually  
107 used simple linear fitting. In a literature review, a pattern on a chart should be given more paying attention.

108

109

## 110 **Main text**

### 111 **Introduction**

#### 112 ***Research question and hypothesis***

113           Thrombosis research has a relatively long history in medicine. In the 19th century, Virchow’s triad,  
114 named after Rudolf Virchow (1821-1902), was a principle for thrombus development (“Hypercoagulability,”  
115 “Stasis,” and “Endothelial injury”)(14, 15), had already been established.

116           However, controversy has remained in “traveler’s thrombosis (travel-related thrombosis)” (**Supporting**  
117 **discussion 1: history of traveler’s thrombosis**)(1-8, 13, 16-24). Clark et al. noted no solid evidence in their  
118 article *"Long-haul travel and venous thrombosis: What is the evidence?"* (1). Despite traveler’s thrombosis being  
119 well-known among medical professionals and the public as “economy class syndrome,” remaining controversial  
120 seemed strange. Also, considering some controversy (14, 15, 25-29) about recent COVID-19-related thrombosis  
121 research, the situation seemed like that of the traveler’s thrombosis (**Supporting discussion 2: research**  
122 **situations of COVID-19-related thrombosis**).

123           We hypothesized something might be seriously overlooked behind those strange situations.

124

#### 125 ***Making a “review strategy” to find out something overlooked***

126           However, trying ordinary review methods (e.g., systematic review or meta-analysis) again seemed  
127 impractical to extract something overlooked because those types of the study had already been conducted (2-7).  
128 So, a novel strategy seemed to be needed.

129           Firstly, we focused on reviewing “figures.” Usually, numerical data in tables within each piece of  
130 literature are evaluated in a meta-analysis. However, figures created by each researcher are generally not. Also,  
131 seeing the chart is more difficult than we thought (30).

132           Recently, there has been software that detects research fraud in the figures submitted for journals (31),  
133 but it does not discover “overlooked findings.” Also, although raw data images, such as CT or MRI images, were  
134 analyzed, there is no awareness of new information extraction from the “previously published” “chart.” So, it  
135 seemed helpful for novel method development that reviewing previously published charts to find unknown  
136 information.

137           Secondary, we focused on geometry. Although statistics usually have applied to medicine (e.g., p-  
138 value), approaching from a different direction seemed helpful when ordinary methods do not work.

139 We finally made our original strategy, which was extracting overlooked knowledge from the  
140 “previously published” “chart” by “geometrical viewpoint” (**Fig. S1, a-c**).

141  
142 ***Developing a novel “review method” for meta-regression analysis result***

143 Considering the above strategy, we focused on a figure that showed a result of meta-regression analysis  
144 (**Fig. S1, b**)(Chandra et al., *Ann Intern Med.* 2009;151(3):180-90., Figure 3) (3). In this figure, we saw a  
145 geometrical shape (layered hyperbolic shapes) that seemed to be formed by two subgroups (**Fig. 1, Fig. 3, a**).  
146 Also, we conceived a methodology, which was a manually executable kind of pattern recognition, searching  
147 layered hyperbolic patterns in a figure that shows a result of meta-regression analysis to detect latent sub-groups.  
148 Our basic idea is that a confidence interval length for an odds ratio is inversely proportional to the “potential  
149 patient population size” (see **Fig. S2, d-f**) (Details in **Methods**).

150  
151 ***Our report in this article***

152 This article shows the results of applying our strategy and method (**the overall study framework is**  
153 **demonstrated in Fig. 2**).

154  
155 **Methods**

156 Deriving the exact formula directly was difficult. So, firstly we focused only on the U-shaped curve.  
157 The length of the confidence interval for the odds ratio is inverse proportional-like to the size of the potential  
158 patient population, which onset thrombosis by exposure to risk factors (see **Fig. 1**). Although, there are multiple  
159 possibilities (e.g.,  $1/N$ ,  $1/N^2$ , or  $1/\sqrt{N}$ ), regarding the form of equations (1) and (2) below, we intuitively  
160 predicted that it would be approximately equal to the inverse of the root (equation (3)).

161  
162 
$$\text{Log}_e(95\%CI) = \text{Log}_e(OR) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \quad (1)$$

163  
164 
$$\sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} = \frac{\sqrt{bcd+acd+abd+abc}}{\sqrt{abcd}} = \frac{\text{complex combination of numbers}}{\sqrt{abcd}} \quad (2)$$

165  
166 
$$\text{Log}_e(95\%CI) = \text{Log}_e(OR) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \cong \text{Log}_e(OR) \pm 1.96 \times \frac{1}{\sqrt{N}} \quad (3)$$

167

168 To be precise, the ability of patient recruitment, in other words, the “sample size in each study,” affects  
169 the confidence interval length.

170 It is similar to Hooke’s law on spring (32), which states that the pull-back force of spring is  
171 proportional to the length of the pull. In this case, the power also depends on the spring type (e.g., thick spring or  
172 thin spring). Thus, the formula is as follows, with spring constant (k) depending on the kind of spring (equation  
173 (4)). Similarly, equation (3) express equation (5) precisely.

174

$$175 \text{Force} = k \times \text{Distance} \quad (4)$$

176

$$177 \text{Log}_e(95\%CI) = \text{Log}_e(OR) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \cong \text{Log}_e(OR) \pm 1.96 \times \frac{k}{\sqrt{N}} \quad (5)$$

178

179 However, we speculated that the effect of the differences in sample size could not be a practical  
180 problem for two reasons.

181 The first reason is that stratified analysis, often performed in clinical studies, can be a force in reducing  
182 the differences. The second reason is that two types of boundary conditions in the hyperbolic shape fitting, which  
183 are the “S-curve” and the “error bar length,” reduce the degree of freedom in searching and increase the  
184 possibility of finding the desired shape.

185 Considering the numerical experiment (see **Results - Numerical Experiment**), we decided on the  
186 equations for the S-shaped curve, the upper end of the confidence limit, and the lower end of the confidence limit  
187 (equation (1), (2), and (3)). Note that in the below equations, the coefficient L is generally set as 1. So, we used  
188 this equation under the condition of L=1 unless there is some reason.

189

$$190 y = \left\{ \frac{K_1}{1+e^{L(x-M)}} + K_2 \right\} \quad (6)$$

$$191 y = \left\{ \frac{K_1}{1+e^{L(x-M)}} + K_2 \right\} + (ax^2 + bx + c) \quad (7)$$

$$192 y = \left\{ \frac{K_1}{1+e^{L(x-M)}} + K_2 \right\} - (ax^2 + bx + c) \quad (8)$$

193

194 The whole process, including, data review, regression analysis, and tools for the analysis, is described in the  
195 supplementary information (**Supporting information: Method details**).

196

## 197 **Results**

### 198 **Numerical Experiment**

199 Usually, a sigmoid function is used for curve fitting to a dose-response relationship and outline of the  
200 cumulative distribution. Also, the curve expressing the end of a confidence interval is a sum of the S-shaped and  
201 U-shaped curves (**see Fig. 1**).

202 To decide on a formula to express a U-shaped curve, we performed a numerical experiment. The result  
203 indicated that a parabola could approximate a U-shaped curve (**Fig. 1, c & d**). We constructed three  
204 mathematical formulas for fitting hyperbolic patterns to data (**see Fig. 1 and Methods**).

205

### 206 **Analysis 1A (dataset: Chandra et al.) (3)**

207 Before redrawing the figures of the meta-regression analysis, we reviewed the cited four studies  
208 (Martinelli et al., 2003; Parkin et al., 2006; Cannegieter et al., 2006; Kuipers et al., 2007) (8, 13, 17, 33). The  
209 main objective of Chandra et al.'s research (3) was estimating a risk, but the main of our analysis is detecting the  
210 subgroups. So, we are considering the possibility of some problems with inclusion in our study, even if there  
211 were no problems in Chandra et al.'s research.

212 In this assessment, two study data (Martinelli et al., 2003; Cannegieter et al., 2006) (8, 13) were judged  
213 inappropriate and excluded from our analysis. Cannegieter et al. and Martinelli et al. used a unique research  
214 design, which uses the patient's partner as a control (Martinelli et al.: friend and partner). In the introduction, we  
215 described that although the properties of each study (the ability of patient recruitment, sample size) disrupt the  
216 effect of the size of the potential patient population, the stratified analysis could reduce the disruption. However,  
217 the impact of adding a unique study design was unclear.

218 Additionally, the odds ratio reported by Parkin et al. (33) was suspected to be affected by the  
219 misplacement of the cells in the cross table for calculating the odds ratio. Still, qualitatively, it could be used (**see**  
220 **Fig. 2, Table S1, Table S2, and Supporting information: Method details**).

221 In the residual dataset (Parkin et al., 2006 & Kuipers et al., 2007)(17, 33), layered hyperbolic patterns  
222 appeared, and applied regression analysis with the above three formulas. The inflection points of the S-curves  
223 (center of distributions) were 7.1 hours and 11.8 hours, respectively (**Fig. 3, b**).



224 Additionally, it seemed that S-curve could be fitted to the group of points reported by Cannegieter et al.  
225 and Martinelli et al., respectively. Also, those of inflection points would position at positions of less than 10  
226 hours and more than 10 hours. This result seems consistent with the two hyperbolic shapes fitting (**Fig. 3, b,**  
227 **orange, and green dots**).

228 Notably, we observed an overlooked cyclic pattern of thrombosis onset in the figure reported by  
229 Cannegieter et al. (2) during the above data review process. The cycle period was 27.4 days (**Fig. 4, a-e**). The  
230 wave of about 28 days consisted of a gradually decaying wave and a monotonically decreasing function (**Fig. 4,**  
231 **e**). The wave disappeared after about three months (90 days). The monotonically decreasing part estimated that it  
232 continued for over 90 days after the travel (**Fig. 4, f**). Cannegieter et al. (2) did not mention this wave pattern.

233

#### 234 **Analysis 1B (dataset: Philbrick et al.) (4)**

235 Considering that only a few pieces of data were available for the first analysis, we performed a similar  
236 analysis using another dataset gathered by Philbrick et al. for a systematic review. As a preparation, we  
237 conducted a data review to confirm eligibility for our regression analysis (**see Fig. 2**). The dataset did not contain  
238 risk ratio data. In this case, hyperbolic shapes could not be fitted (for the details, see **Supporting information:**  
239 **Method details**). So, only S-curves were applied. This analysis found two S-curves in the stratified datasets by  
240 pulmonary embolism (PE) and deep vein thrombosis (DVT). The inflection point of PE was about 9.2 hours, and  
241 the point of DVT was about 12.1 hours, respectively (**Fig. S3, b**), which were similar to the first analysis.

242 Additionally, we found that unrecognized periodic pattern in the data reported by Clérel and Caillard  
243 (34) during the data review, which was suspected to be the effect of circadian rhythm (**Fig. S4, c**).

244 We also found a cyclic pattern after travel in the data reported by Kelman et al. (9). However, the  
245 period of the wave was 17.9 days, and the wave was less clear than the wave observed in the data reported by  
246 Cannegieter et al. In the waveform, there was a raw-risk period just before 90 days. Also, in this data, there was  
247 an uptrend (**Fig. 5**).

248 Furthermore, we found a correlation between the stepped stages of increasing PE patients and the  
249 issuance of the guidelines (35-38) for preventive hormone replacement therapy (HRT) to a menopause woman in  
250 a figure reported by Clérel and Caillard (34) (**Fig. S5**). Especially the thrombosis onset in Paris airports has  
251 increased since the late 1990s (**Fig. S5**).

252

253 **Analysis 1B-related additional analysis**

254 ***Trend analysis and history of sex ratio change***

255 We performed the trend analysis of the literature to assess the generalization on the increasing number  
256 of patients at Paris airports reported by Clérel & Caillard (34) (**Fig. S5**). We searched the literature in PubMed  
257 (keywords: “Economy Class Syndrome,” “Traveler’s Thrombosis,” and “Travel-related thrombosis”). The  
258 number of references increases rapidly after the 2000s (**Fig. S6**).

259 The difference between the above result of trend analysis and the result in the data reported by Clérel  
260 and Caillard (34) can be explained by the difference between publication day and onset day. So, there is no  
261 practical difference between the two results.

262 The literature search found that two articles (Symington & Stack, 1977, Cruickshank, Gorlin, &  
263 Jennett, 1988) (12, 39) contained each patient’s details. We already obtained each patient’s data from the other  
264 two articles in analyses 1A and 1B (Clérel & Caillard, 1999, Parkin et al., 2006) (33, 34). So, we confirm  
265 changing the sex ratio using those data to assess the effect of HRT. We found that the rate of women in the PE  
266 data gathered from the above four studies (12, 33, 34, 39) gradually increased but was most pronounced during  
267 the late 1990s (**Table 1**).

268

269 **Table 1**

270 **Table 1. Changing female percentage from four studies reported in the 1970s to 2000s.**

Author	Year	Total N	Male		Female		Larger one
			Male N	%	Female N	%	
Symington & Stack ( <b>39</b> )	1977	n=8	n=5	62.5%	n=3	37.5%	Male
Cruickshank et al. ( <b>12</b> )	1988	n=6	n=5	83.3%	n=1	16.7%	Male
Clérel & Caillard ( <b>34</b> )	1999	n=64	n=15	23.4%	n=49	76.6%	Female
Parkin et al. ( <b>33</b> )	2006	n=11	n=4	36.4%	n=7	63.6%	Female

271

272 ***Literature review targeting early literature and analysis focusing on men***

273 We also conducted a literature review targeting early literature because we strongly questioned the  
274 “economy class syndrome” concept from our findings in Analysis 1A and 1B. We found that the word appeared  
275 in Symington & Stack, 1977 (39). However, judging from the citation history checked on the Europe PMC  
276 website (<https://europepmc.org/>), the article by Cruickshank, Gorlin, & Jennett, 1988 (12) might influence the

277 word as evangelists. The paper was a “personal paper,” a type of article category of the Lancet, and the authors  
278 prepared case reports of their own experiences.

279 Dr. Cruickshank was middle-aged (12). Usually, the mid-life crisis is concerned around this range of  
280 age. Dr. Jennett was a dean of medicine at Glasgow (40). Generally, heavy psychological stress based on heavy  
281 social responsibility is concerned. So, we hypothesized that men’s life event-related psychological stress could  
282 be one of the risk factors (see **Fig. S7, b**).

283 To assess our hypothesis, we merged data from the above four studies (12, 33, 34, 39) and made a bar  
284 chart for 1-year. The onset of PE was concentrated in certain age stages, such as around 30, the 40s, late 50s, and  
285 early 70s (**Fig. S7, e**).

286 We performed the same analysis in the women’s data except for data reported by Clérel & Caillard  
287 (34). Although the peak range was 65 to 70 in the data of Clérel & Caillard (34) (**Fig. S4, d**), PE was  
288 concentrated in the 40s to 50s (menopausal stage) in this analysis (**Fig. S8**).

289 Additionally, we found an inverted-U-shaped (mountainous) relationship in the scatter plot: age on the  
290 horizontal axis and air travel time on the vertical axis (**Fig. S10, d**). However, it was possible to fit a straight line  
291 as an up-right linear relationship or a down-right linear relationship (**Fig. S9, a, and Fig. S10, a, c**).

292 These analyses were also performed on the female data reported by Clérel & Caillard (34), and we  
293 found a U-shaped relationship (**Fig. S9, c**).

294

## 295 **Analysis 2 (dataset: COVID-19) (41)**

296 We decided to apply our ideas to the current complex COVID-19 pandemic problem to find some  
297 overlooked things because there was some controversy (14, 15, 25-29) about COVID-19-related thrombosis.  
298 This situation was similar to that of the traveler’s thrombosis, and we started this analysis with the inspiration  
299 from the famous mathematician Polya who stated that solving a similar problem helped us solve a more complex  
300 problem (42).

301 As a note, we described that stratified is necessary for the introduction section, but clinical studies of  
302 COVID-19 did not perform it. However, Stratification seemed unnecessary because the size of the studies was  
303 not huge and roughly the same due to no mega trial during the pandemic.

304 One of us (KK) searched for the layered hyperbolic pattern using the search engine Google and  
305 extracted a figure reported by Matsushita et al. (41) (**Fig. 6, a-c**). After evaluating eligibility (see **Fig. 2**), patterns  
306 that allowed to be fitted hyperbolic shapes appeared (**Fig. 6, d-f, & g-i**).

307 Considering the cause of these patterns, we found the matching between grouping the data by  
308 hyperbolic patterns and grouping by data cut-off days (**Fig. S11**). We calculated weighted averages of age by  
309 grouping. In the earlier days group, non-severe was 46.5, and severe was 57.7, which were middle age (age 45-  
310 64). In the late date group, non-severe was 40.9, and severe was 68.6, which were mature age (age 25-44) and  
311 elderly (age > 65), respectively.

312 Surprisingly, we found unrecognized patterns during the data review process in a figure reported by  
313 Guo et al. (10), which showed a relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and  
314 Troponin T (TnT). There were three clusters of subgroup patterns, and each cluster could be fitted parabola (**Fig.**  
315 **7 a, b, Fig. S12, a, b & Fig. S13, a, d, e-h**).

316 The third subgroup pattern was similar to ST-elevating myocardial infarction in the figure report by  
317 Budnik et al. (11). That study was a comparative study between Takotsubo cardiomyopathy (also known as  
318 stress cardiomyopathy or broken heart syndrome) and ST-elevating myocardial infarction. This tilted parabola  
319 appeared in another study on COVID-19 patients (**Fig. S12, c**) (43), and the pattern had already appeared in  
320 other studies (44, 45) before the pandemic (**Fig. S13, b & c**). However, patterns in COVID-19 patients were not  
321 recognized by each author.

322 Additionally, In the case of dropping points to the horizontal axis (troponin axis), the histogram on the  
323 troponin axis results in bimodality. The above results matched the patterns reported by other studies (**Fig. S12, d**  
324 **& e**) (43, 46, 47).

325 Furthermore, by mounting the data of high-sensitivity C-Reactive protein (hsCRP) onto the third  
326 subgroup in the data reported by Guo et al. (10) and constructing a parabolic cylinder, we found a pattern that  
327 might further be subdivided into two subgroups on the side surface of this parabolic cylinder (**Fig. 7, c, d, & Fig.**  
328 **S14**).

329

## 330 Discussion

### 331 *Hyperbolic shape fitting in traveler's thrombosis*

332 In traveler's thrombosis, we obtained consistent results from two analyses (Analysis 1A: 7.1 hours and  
333 11.8 hours, Analysis 1B: 9.2 hours and 12.1 hours) (**Fig. 3, b, Fig. S3, b**). The discrepancy between the value of  
334 7.1 hours and 9.2 hours seems to be explained by the miscalculation found in the data review process (**see Table**  
335 **S1, Table S2, and Supporting information: Method details**). Our results implied two S-curves. Also, we  
336 hypothesized two high-risk periods and two types of high-risk groups, which may have to be considered with the

337 “factor V Leiden paradox” (48) (**Supporting discussion 3: two high-risk periods and two types of high-risk**  
338 **groups?**).

339

#### 340 *Cyclic patterns newly founded in this research and OC*

341 Another noteworthy point is the cyclic patterns in the data reported by Cannegieter et al. (8) (**Fig. 4**). In  
342 Cannegieter et al. (8), the cyclic pattern disappeared around three months (90 days), consistent with the high-risk  
343 period in oral contraceptive (OC) use was the first three months (49). Since there is multi-phase OC in the  
344 category of OC, our findings imply that the 28 days cycle OC is attributable to the cyclic pattern.

345 Additionally, the low-risk period just before 90 days in the data reported by Kelman et al. (9) (**Fig. 5**).  
346 This low-risk period could be explained that extended-use type OC, which has a planned drug withdrawal, such  
347 as 84 active days and seven placebo days (50, 51).

348 The uptrend in the data by Kelman et al.(9) might be due to depot agent type OC administered in 90  
349 days cycle, which injects drugs periodically after decreasing the drugs in the body.

350 Based on the above results, types of OC use (multi-phase type, extended-use type, and depot agent  
351 type) might be triggered by travel.

352 The data reported by Cannegieter et al. contained many car trips (air travel, train, bus, and car trip).  
353 These cars might be honeymoon cars.

354 Kelman et al. described that although the risk increased within 2 to 4 weeks of flight (hazard period),  
355 the risk was low after the period because travelers were healthier than the average of a group (healthy traveler  
356 effect) (9). Also, Rothman mentioned the “persistence of travel-related risk” and “spline regression” (16). They  
357 might realize the position around 3-4 weeks as a valley between two distributions (honestly, we thought the same  
358 as them before we learned the cyclic patterns by spending long-time severe observations and non-linear  
359 regression analysis).

360

#### 361 *The difference in the cyclic patterns and HRT*

362 Interestingly, there was a difference between the period of cyclic patterns (Cannegieter et al.: about 28  
363 days, Kelman et al.: about 18 days). Also, the wave in the data reported by Cannegieter et al. was clear, but the  
364 wave in the data reported by Kelman et al. was not clear despite the exposures in Cannegieter et al. being more  
365 complex (air travel, train, bus, and car trip) (8) than Kelman et al. (only air travel) (9).

366           Regarding the halfway cycle (about 18 days) in Kelman et al. (9), it is notable that a combination of  
367           daily estrogen dosing and 10–14 days of progestogen (52) is used for HRT. Also, in 1999, Clérel and Caillard  
368           mentioned that OC and HRT might affect thrombosis after travel (34).

369           It is also notable that thrombosis onset in the data reported by Cannegieter et al. was “March 1999-  
370           March 2000” (only most late 1990s to early 2000) (8). Thrombosis onset in the data reported by Kelman et al.  
371           was “1981-1999” (including the whole of the 1990s) (9).

372           We found a slowdown of the increase of thrombosis onset at Paris airports in 1998, the year of HERS  
373           result was issued (**Fig. S5**). Also, our trend analysis showed that the number of literature on thrombosis  
374           decreased since around 2000 (**Fig. S6**). Moreover, our merged data from four studies (12, 33, 34, 39) on PE  
375           from the 1970s to the 2000s showed that the rate of women was most pronounced during the late 1990s (**Table**  
376           **1**).

377           Therefore, the difference in waves can be explained as follows: the halfway cycle (17.9 days) in  
378           Kelman et al. (9) was a mixture of the 28 days OC cycle and a type of HRT cycle. However, only OC users  
379           might remain in the data reported by Cannegieter et al. (8) after the issue of the HERS study in 1998 (37).

380           Although the existence of the women patients not “menopausal” stage women (40s to 50s) but among  
381           around 70-75 years of age seems to disagree with HRT use (**Fig. S4, d, & Fig. S8, d**), the subjects of the WHI  
382           study were “postmenopausal” women (age 50-79) for prophylactic use for cardiovascular problems.

383

#### 384           *Men’s life stage and travel related psychological stress*

385           Analysis 1B-related additional analysis suggested that the development of travel-related thrombosis  
386           occurs at specific ages (**Fig. S7**). On the other hand, Kelman et al. reported the incidence of VTE per 100,000  
387           passengers (9). In this data (9), the incidence of VTE sharply increased after age 40, and it was a temporary  
388           decrease in the early 60s. Although it should be noted that these results are not limited to men, they are  
389           consistent with our results.

390           We also found that the relationship between male age and travel duration seems to be inverted-U-  
391           shaped (mountainous) (**Fig. S9 & Fig. S10**). Regarding this result, men’s life event-related psychological stress  
392           may be one of the risk factors.

393           Moreover, every four studies (12, 33, 34, 39) showed inconsistent results (correlated or inversely  
394           correlated). This situation seems to be the same as the parable of “blind men and an elephant.” Considering the

395 correlation between age and the risk of thrombosis, the above phenomena may be one of the causes of  
396 controversial discussions.

397

398 ***Changing the framework of the disease concept of “travel-related thrombosis.”***

399 There has been a widespread belief that in-flight environments cause thrombosis. Also, the  
400 phenomenon of the onset of thrombosis after over a few weeks to two months since the travel has been  
401 explained, such as the development of blood clots occurring on a cabin, but the dislodge of a thrombus occurs  
402 after (12). Also, although OC-related thrombosis had already been known, OC was recognized as not a  
403 substantial cause but one of the risk (aggravating) factors (13).

404 Other researchers might realize other possibilities changed the name of thrombosis after travel from  
405 “traveler’s thrombosis” to “travel-related thrombosis,” but they could not show evidence.

406 However, the above cyclic patterns of thrombosis onset may suggest that the disease concept of  
407 traveler’s thrombosis (travel-related thrombosis) should be changed. From the cyclic patterns, it is more  
408 reasonable to explain that the “travel” and “high-risk period of thrombosis with OC use (within three months  
409 from starting OC)” coincided with the travel (e.g., honeymoon and starting birth control OC).

410 On the other hand, although the results of a meta-regression analysis (Chandra et al.’s result (3) and our  
411 results of S-curve fittings) showing that the risk of thrombosis increases with travel duration have seemed to  
412 support the in-flight environment theory, the possibility may exist that what essentially correlates with the risk of  
413 thrombosis is “increased health risks with aging” or “psychological stress associated with rising job titles,” since  
414 men’s data shows an increase in travel time with age. Nemeth et al. experimentally showed that psychological  
415 stress (fear caused by a horror movie) was associated with a rise in blood coagulant factor VIII (53).

416 Recently, Er et al. reported a few cases of venous thromboembolism (VTE) incidence during the  
417 COVID-19 lockdown (54). However, all patients had inter mediate-high risk pulmonary embolisms. Therefore,  
418 the influence of the in-flight environment may be less than we had previously thought. From a comprehensive  
419 view, “traveler’s thrombosis” or “travel-related thrombosis” may require to be regarded as “life-event-related  
420 thrombosis.”

421 Even if a substantial risk factor is not the in-flight environment, it is not neglectable at the present  
422 research stage. Our thought that starting OC or HRT was triggered by travel suggests that usage based on risk  
423 diversification is important to avoid overlapping risks of drug and in-flight environment. Also, well-planned may



424 allow more safe use of OC and HRT. Additionally, for men, perhaps we should focus more on “stress  
425 reduction.”

426

#### 427 *Application of our method for COVID-19 cardiovascular data*

428 In applying our ideas for COVID-19, the dataset grouping by Matsushita et al.(41) matched the  
429 grouping by data cut-off dates (**Fig. S11**). Age structure diverged from middle age to mature and elderly.  
430 Middle-aged people (age 45-64) might enter the workforce for manual labor treating fish containers, mature  
431 people (age 25-44) might want to select IT jobs, and elderly people (age > 65) might stay in the house. So, our  
432 results were consistent with the hypothesis that COVID-19 spread from the seafood market.

433 In our data review process (**Supporting discussion 4: linear regression analysis**), our analysis of the  
434 data reported by Guo et al. (10) showed three clusters of subgroups and formed the tilted parabola. Also, the  
435 patterns matched the other studies (**Fig. 7 a, b, Fig. S12 & Fig. S13**) (11, 43-47). Considering the study by  
436 Budnik et al. (11), those subgroups may have different biological mechanisms. Also, we found patterns on the  
437 side surface of this parabolic cylinder (**Fig. 7, c, d, & Fig. S14**).

438 On the other hand, a paradoxical result on troponin was obtained just before the pandemic (55). Meisel  
439 et al. mentioned that the CRP to troponin ratio (CRP/troponin) could serve to differentiate between  
440 myopericarditis and acute myocardial ischemia (AMI), although not the study on COVID-19 patients. In  
441 COVID-19, Caro-Codón et al. reported interesting behavior of CRP (46). A meta-analysis by Lagunas-Rangel  
442 reported that the lymphocyte-to-C-reactive protein ratio (LCR) level, which was not a simple measurement value  
443 but a ratio, might be related to an inflammatory process (56).

444 The above studies might imply complex data structures in 2-dimensional and 3-dimensional scatter  
445 plots consisting of biomarker values, and our findings may serve the cardiac biomarkers’ research field.

446 Supplementary, our result suggested that the treatment of implicit function, which is unfamiliar in the  
447 medical and biological fields, is required. In this research, we used our method to fit the curves. However, a  
448 Fortran program created by Dr. Timmes (57), a researcher in astronomy, may also be helpful for future research.

449

#### 450 *Controversial discussions and overlooked patterns*

451 From the consistent results of Analysis 1A and 1B and the explainable result of analysis 2, it is  
452 conceivable that our strategy and method were effective. Recently, we have thought that the concept of “medical  
453 research test” or “inspection of medical data analysis” can be developed analogically as an extension of the



454 medical inspection, including laboratory tests for each patient for each patient. Like medical inspection using  
455 equipment, detecting overlaid hyperbolic shape patterns may be a tool or marker of some overlooked  
456 information (**Fig. S1, e**).

457 We could not judge whether our findings are the root cause of the remaining controversies in  
458 thrombosis research. However, judging from many findings, when conducting a literature review, although  
459 paying attention to the reproducibility of a pattern in charts is needed to avoid arbitrary discussions, more serious  
460 consideration should be given to a pattern on a chart that has been ignored as a noisy variation.

461

## 462 **Conclusions**

463 In the study of traveler's thrombosis, there has long been a widespread belief that thrombosis is caused  
464 by the in-flight environment (e.g., immobility or dehydration). Also, the phenomenon of the onset of thrombosis  
465 after a long period since the travel, which seems to contradict the above idea, has been explained in a somewhat  
466 forced way, such as the formation of blood clots occurs on board the airplane but the dislodge of blood clots  
467 occur after the travel.

468 However, from our analysis results of the variation of bar charts which present the number of  
469 thrombosis cases, it is a more reasonable explanation that the travel and the initiation of oral contraceptive (OC)  
470 use were strongly linked so that the "travel" and "high-risk period of thrombosis with OC use" coincided with  
471 the travel. Also, although the results of a meta-regression analysis showing that the risk of thrombosis increases  
472 with travel duration have seemed to support the in-flight environment theory, the possibility may exist that what  
473 essentially correlates with the risk of thrombosis is aging or psychological stress associated with rising job titles,  
474 since men's data shows an increase in travel time with age. Therefore, the influence of the in-flight environment  
475 may be less than we had previously thought.

476 Although simple linear regression analysis has been used in studies of cardiovascular biomarkers,  
477 including the case of COVID-19, based on the results of our observations by focusing on the reproducibility of  
478 patterns on scatterplots or by reconstructing 3D scatterplots from data on several panels, it seems that there is a  
479 complex scatterplot structure that does not suitable for simple linear fitting.

480 We could not judge whether our findings are the root cause of remaining controversial discussions in  
481 thrombosis research. However, regarding our findings, paying more attention to patterns in the chart is needed.

482

483

## 484 **Acknowledgments**

485 One of the authors, Keiichiro Kimoto, appreciates the kindful encouragement of Hideo Yoshioka,  
486 MEcon., who is in charge of the Data Strategy Research Institute representative.

487

## 488 **Statement of our intention for data analysis results on previous published articles.**

489 In addition to general acknowledgments, to clarify our stance, we mention this statement of intention  
490 for results. In this article, we pointed out many overlooked information and errors. However, we have no  
491 intention to attack previous works because our analysis results owing to their original works, including original  
492 research articles, reported valuable data, and writings of meta-analysis synthesized valuable datasets. Since just a  
493 scientist had better reconfirm the previous studies with no preconceptions and being grateful to those studies'  
494 researchers, we carefully reviewed the data reported by previous studies. We highly respect previous works  
495 intending to solve medical issues.

496

## 497 **Transparency declaration**

498 This study was not required ethical approval because the study used ONLY two types of openly  
499 available human data. Firstly, this study performed meta-analyses as secondary analyses. The source of the data  
500 was described in the method section. Second, this study analyzed measured values from figures in previous  
501 published scientific papers.

502 All the figures were appropriately treated with careful attention to the copyright issues to protect the  
503 integrity of the science. The sources of the original articles were described in the figure legend following the  
504 copyright holder's instructions. Also, we submit copyright details in another file to a journal that we submit this  
505 manuscript file to explain additional information.

506 This study suggests a new review strategy and meta-analysis method for exploratory data analysis and  
507 reports some epidemiological findings. So, there were no applicable guidelines (e.g., Preferred Reporting Items  
508 for Systematic reviews and Meta-Analyses, PRISMA). However, this study carefully follows the usage of the  
509 statistical analysis method, and the whole process is precisely described in the method details section and **Fig. 2**.

510 This study was not received financial support from any funding.

511

512 **Data availability statement**

513 We analyzed clinical data published by other studies (third parties). Used data is identified by indicated  
514 information of citation (reference numbers and list of references). The corresponding author responds to  
515 inquiries in the case of measured values from published figures requested by reviewers or readers.

516

517 **Code availability statement**

518 Correspondence author (KK) can respond to inquiries for the corresponding author's email address on  
519 offering the Python source code and spreadsheet software files for statistical analysis. Also, we have already  
520 uploaded our Python programs for the following GitHub repository to keep traceability perfectly.

521 [https://github.com/Keiichiro-KIMOTO-Kagoshima-University/Findings\\_in\\_Travel-](https://github.com/Keiichiro-KIMOTO-Kagoshima-University/Findings_in_Travel-related_Thrombosis_and_COVID-19_Related_Cardiac_Biomarker_Data)  
522 [related\\_Thrombosis\\_and\\_COVID-19\\_Related\\_Cardiac\\_Biomarker\\_Data](https://github.com/Keiichiro-KIMOTO-Kagoshima-University/Findings_in_Travel-related_Thrombosis_and_COVID-19_Related_Cardiac_Biomarker_Data)

523

524

525

526 **References**

- 527 1. Clark SL, Onida S, Davies A. Long-haul travel and venous thrombosis: What is the evidence?  
528 Phlebology. 2018;33(5):295-7.
- 529 2. Kuipers S, Schreijer AJ, Cannegieter SC, Büller HR, Rosendaal FR, Middeldorp S. Travel and venous  
530 thrombosis: a systematic review. J Intern Med. 2007;262(6):615-34.
- 531 3. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism.  
532 Ann Intern Med. 2009;151(3):180-90.
- 533 4. Philbrick JT, Shumate R, Siadaty MS, Becker DM. Air travel and venous thromboembolism: a  
534 systematic review. J Gen Intern Med. 2007;22(1):107-14.
- 535 5. Adi Y, Bayliss S, Rouse A, Taylor RS. The association between air travel and deep vein thrombosis:  
536 systematic review & meta-analysis. BMC Cardiovasc Disord. 2004;4:7.
- 537 6. Spencer FA. Review: Flight times >8 hours and presence of risk factors for VTE increases travel  
538 related VTE. Evid Based Med. 2007;12(4):105.
- 539 7. Trujillo-Santos AJ, Jiménez-Puente A, Perea-Milla E. Association between long travel and venous  
540 thromboembolic disease: a systematic review and meta-analysis of case-control studies. Ann Hematol.  
541 2008;87(2):79-86.
- 542 8. Cannegieter SC, Doggen CJ, van Houwelingen HC, Rosendaal FR. Travel-related venous thrombosis:  
543 results from a large population-based case control study (MEGA study). PLoS Med. 2006;3(8):e307.
- 544 9. Kelman CW, Kortt MA, Becker NG, Li Z, Mathews JD, Guest CS, et al. Deep vein thrombosis and air  
545 travel: record linkage study. BMJ. 2003;327(7423):1072.
- 546 10. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes  
547 of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-8.
- 548 11. Budnik M, Kochanowski J, Piatkowski R, Wojtera K, Peller M, Gaska M, et al. Simple markers can  
549 distinguish Takotsubo cardiomyopathy from ST segment elevation myocardial infarction. Int J Cardiol.  
550 2016;219:417-20.
- 551 12. Cruickshank JM, Gorlin R, Jennett B. Air travel and thrombotic episodes: the economy class  
552 syndrome. Lancet. 1988;2(8609):497-8.

- 553 13. Martinelli I, Taioli E, Battaglioli T, Podda GM, Passamonti SM, Pedotti P, et al. Risk of venous  
554 thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. *Arch Intern*  
555 *Med.* 2003;163(22):2771-4.
- 556 14. Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through  
557 the prism of Virchow's triad. *Clin Rheumatol.* 2020;39(9):2529-43.
- 558 15. Kushner A, West WP, Pillarisetty LS. Virchow Triad. In: *StatPearls [Internet]*. 2021.
- 559 16. Rothman KJ. Thrombosis after travel. *PLoS Med.* 2006;3(8):e300.
- 560 17. Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR. The absolute risk of  
561 venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations.  
562 *PLoS Med.* 2007;4(9):e290.
- 563 18. Gore JM. Travel and Venous Thromboembolism. *NEJM Jounal Watch.* 2009.
- 564 19. Vandembroucke JP, Cannegieter SC, Rosendaal FR. Travel and venous thrombosis: an exercise in  
565 thinking about bias. *Ann Intern Med.* 2009;151(3):212-3.
- 566 20. New DVT Guidelines: No Evidence to Support Economy Class Syndrome [press release]. 2012.
- 567 21. Crowther M. A Inserted Comment "Traveling in economy class does not increase your risk for  
568 developing a blood clot, even during long-distance travel; however, remaining immobile for long  
569 periods of time will" Retrieved from the Press Release of the American College of Chest Physicians  
570 "New DVT Guidelines: No Evidence to Support Economy Class Syndrome". In: *Physicians ACoC,*  
571 *editor.* 2012.
- 572 22. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical  
573 patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest  
574 Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e195S-e226S.
- 575 23. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al.  
576 American Society of Hematology 2018 guidelines for management of venous thromboembolism:  
577 prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv.* 2018;2(22):3198-225.
- 578 24. Reyes NL, Beckman MG, Abe K. Travel by Air, Land & Sea. In: *Centers for Disease Control and*  
579 *Prevention (CDC), Brunette GW, Nemhauser JB, editors. CDC Yellow Book 2020 Health*  
580 *Information for International Travel.* New York, United States of America: Oxford University Press;  
581 2019.

- 582 25. Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management  
583 of coagulopathy in COVID-19: A comment. *J Thromb Haemost.* 2020;18(8):2060-3.
- 584 26. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on  
585 recognition and management of coagulopathy in COVID-19. *J Thromb Haemost.* 2020;18(5):1023-6.
- 586 27. Callaway E, Ledford H, Mallapaty S. Six months of coronavirus: the mysteries scientists are still  
587 racing to solve. *Nature.* 2020;583(7815):178-9.
- 588 28. Tal S, Spectre G, Kornowski R, Perl L. Venous Thromboembolism Complicated with COVID-19:  
589 What Do We Know So Far? *Acta Haematol.* 2020;143(5):417-24.
- 590 29. Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more  
591 questions than answers. *Intern Emerg Med.* 2020;15(8):1375-87.
- 592 30. Cairo A. *How Charts Lie: Getting Smarter about Visual Information (English Edition)*. New York: W.  
593 W. Norton & Company; 2019.
- 594 31. Van Noorden R. Publishers launch joint effort to tackle altered images in research papers. *Nature.*  
595 2020.
- 596 32. contributors W. Hooke's law - Wikipedia [Available from:  
597 [https://en.wikipedia.org/wiki/Hooke%27s\\_law](https://en.wikipedia.org/wiki/Hooke%27s_law).
- 598 33. Parkin L, Bell ML, Herbison GP, Paul C, Skegg DC. Air travel and fatal pulmonary embolism.  
599 *Thromb Haemost.* 2006;95(5):807-14.
- 600 34. Clérel M, Caillard G. [Thromboembolic syndrome from prolonged sitting and flights of long duration:  
601 experience of the Emergency Medical Service of the Paris Airports]. *Bull Acad Natl Med.*  
602 1999;183(5):985-97; discussion 97-1001.
- 603 35. Guidelines for counseling postmenopausal women about preventive hormone therapy. American  
604 College of Physicians. *Ann Intern Med.* 1992;117(12):1038-41.
- 605 36. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, et al. AHA consensus panel  
606 statement. Preventing heart attack and death in patients with coronary disease. The Secondary  
607 Prevention Panel. *J Am Coll Cardiol.* 1995;26(1):292-4.
- 608 37. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen  
609 plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart  
610 and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA.* 1998;280(7):605-13.

- 611 38. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and  
612 benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the  
613 Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-33.
- 614 39. Symington IS, Stack BH. Pulmonary thromboembolism after travel. *Br J Dis Chest*. 1977;71(2):138-  
615 40.
- 616 40. Professor Bryan Jennett. *British Journal of Neurosurgery*. 2008;22(2):305-6.
- 617 41. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The Relationship of COVID-19 Severity  
618 with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-  
619 Analysis. *Glob Heart*. 2020;15(1):64.
- 620 42. Polya G. *How to Solve It: A New Aspect of Mathematical Method* (Princeton Science Library).  
621 Princeton, New Jersey: Princeton University Press; 1957.
- 622 43. Wang Y, Zheng Y, Tong Q, Wang L, Lv G, Xi Z, et al. Cardiac Injury and Clinical Course of Patients  
623 With Coronavirus Disease 2019. *Front Cardiovasc Med*. 2020;7:147.
- 624 44. Sugawa S, Masuda I, Kato K, Yoshimura M. Increased Levels of Cardiac Troponin I in Subjects with  
625 Extremely Low B-type Natriuretic Peptide Levels. *Sci Rep*. 2018;8(1):5120.
- 626 45. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac  
627 troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients.  
628 *Am J Kidney Dis*. 2007;50(6):1009-19.
- 629 46. Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejon-Castrejon S, et al. Characterization  
630 of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail*. 2021;23(3):456-64.
- 631 47. Demir OM, Ryan M, Cirillo C, Desai N, Pericao A, Sinclair H, et al. Impact and Determinants of  
632 High-Sensitivity Cardiac Troponin-T Concentration in Patients With COVID-19 Admitted to Critical  
633 Care. *Am J Cardiol*. 2021;147:129-36.
- 634 48. van Langevelde K, Flinterman LE, van Hylekama Vlieg A, Rosendaal FR, Cannegieter SC.  
635 Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of  
636 the spectrum. *Blood*. 2012;120(5):933-46.
- 637 49. van Hylekama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous  
638 thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the  
639 MEGA case-control study. *BMJ*. 2009;339:b2921.

- 640 50. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Lange E, et al. Effect of extended-cycle  
641 regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding  
642 patterns, safety, acceptance and contraceptive efficacy. *Contraception*. 2011;84(2):133-43.
- 643 51. Legro RS. *A Review of Extended-Cycle Oral Contraception*. Morrisville, North Carolina, USA; 2003.
- 644 52. Humans IWGotEoCRt. Combined estrogen-progestogen contraceptives and combined estrogen-  
645 progestogen menopausal therapy. *IARC Monogr Eval Carcinog Risks Hum*. 2007;91:1-528.
- 646 53. Nemeth B, Scheres LJ, Lijfering WM, Rosendaal FR. Bloodcurdling movies and measures of  
647 coagulation: Fear Factor crossover trial. *BMJ*. 2015;351:h6367.
- 648 54. Er C, Tan JY, Tan CW, Kaur H, Cheong MA, Lee LH, et al. "Lockdown-thrombosis"-an unexpected  
649 problem of the COVID-19 pandemic? *J Thromb Thrombolysis*. 2022;54(1):29-32.
- 650 55. Perez-Rodrıguez E, Jimenez D, Dıaz G, Perez-Walton I, Luque M, Guillen C, et al. Incidence of air  
651 travel-related pulmonary embolism at the Madrid-Barajas airport. *Arch Intern Med*.  
652 2003;163(22):2766-70.
- 653 56. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in  
654 patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *J Med Virol*.  
655 2020;92(10):1733-4.
- 656 57. Timmes FX. *Fitting to Conic Sections 2021* [2021:[Available from:  
657 [http://cococubed.asu.edu/code\\_pages/conic.shtml](http://cococubed.asu.edu/code_pages/conic.shtml).
- 658 58. Bureau of Labor Statistics USDo, Labor. *The Economics Daily, Men's earnings at peak at age 45-54*  
659 [Available from: <https://www.bls.gov/opub/ted/1999/jul/wk3/art05.htm>.
- 660



661

## 662 **Figures and Tables**

### 663 **Fig. 1**

#### 664 **Fig. 1. A hyperbolic shape formed by confidence limits.**

665 **a**, A two-way cross-tabulation (contingency table) for calculating an odds ratio (OR). **b**, Calculation of OR and  
666 its 95% confidence interval. **c**, Histogram of the data following a binomial distribution and a plot of the inverse  
667 values of the square roots. **d**, The mathematical formulas for the hyperbolic shape. Note that the OR is not  
668 logarithmic, and only the length of the error bar is logarithmic (see the upper left position of panel d). We  
669 generate binomial distribution data because normal distribution could be approximated by binominal  
670 distribution. Around the center of distribution (within  $\pm 2SD$  of the mean), the parabola was a good fit for the  
671 points calculated from the simulated data. Also, from around the over  $\pm 2SD$  to  $\pm 3SD$  range, the parabola is  
672 positioned below the points. Although a catenary curve (dashed curve) is more likely suitable for fit, the number  
673 of patients who fall into the categories at both ends is slightly larger than the expected number. Usually, data  
674 placed over the range of  $\pm 3$  SD from the distribution center are summarized as “greater than” or “less than.” For  
675 example, in the case of 10 hours is the center of the distribution, the time category might be following sets such  
676 as “less than” 5 hours, 6-8 hours, 9-11 hours, 12-14 hours, and “more than” 15 hours. The value of  $1/\sqrt{N}$   
677 ( $1/\sqrt{N}$ ) becomes smaller. So, using a parabola seemed to be based on the reality of the data handling method  
678 in the medical and biological fields.

679

### 680 **Fig. 2**

#### 681 **Fig. 2. Overall framework of this study.**

682 We applied our concepts to travelers' thrombosis and COVID-19. These were similar in research history (see  
683 **Supporting discussion 1: history of traveler's thrombosis & Supporting discussion 2: research situations**  
684 **of COVID-19-related thrombosis**). In the case of traveler's thrombosis, we analyzed a dataset collected by  
685 Chandra et al. and Philbrick et al. (3, 4). In the case of COVID-19, we analyzed a dataset collected by Matsushita  
686 et al. (3). Flow charts show data accept or reject flows. To avoid duplicating data, Matsushita et al. selected only  
687 eight studies data (25 studies included in initial web Figure 5) (41).

688

### 689 **Fig. 3**

#### 690 **Fig. 3. Re-analysis based on the proposed ideas.**

691 **a**, Data review and meta-regression analysis using the same method as Chandra et al. *Ann Intern Med.* 2009;  
692 151(3):180-190. Figure 3 (3). We added information from original studies and our hypothesis to the previously  
693 published form, such as latent distribution. This figure is regarded as a re-drawn figure from Chandra D, Parisini  
694 E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. *Ann Intern Med.* 2009 Aug  
695 4;151(3):180-90. doi: 10.7326/0003-4819-151-3-200908040-00129. Epub 2009 Jul 6. © 2009 American College  
696 of Physicians. Adapted with permission. The original figure has been shown on the American College of  
697 Physicians website, which links to PubMed® (<https://pubmed.ncbi.nlm.nih.gov/19581633/>). **b**, grouping the  
698 data and hyperbolic shape fitting. The dots represent the odds ratio with error bars of the confidence interval are  
699 the adjusted odds ratio described in the four studies cited by Chandra et al. Since Cannegieter et al. did not  
700 describe values of confidence intervals, we calculated the values from the case-count data. We also calculated  
701 the odds ratio at the time point of short travel in the research reported by Martinelli et al. Chandra et al. did not  
702 display it might be due to the no adjusted odds ratio initially described. Our result of a meta-regression analysis  
703 was slightly different from the straight line drawn by Chandra et al. might be due to the software used by  
704 Chandra et al. (STATA) being different from the one we used (R and R package “metafor”) or they might  
705 conduct a meta-regression analysis reversing the front head and the front side of the cross-tabulation. It was  
706 impossible to fit S-shaped curves for the points excluded from the search for hyperbolic shapes (Martinelli et al.  
707 & Cannegieter et al.) due to the small number of data or the form of the point sequence. However, if we  
708 manually fit S-curves, the two inflection points would appear close to the positions of the hyperbolic shapes’  
709 inflection points.

710

711 **Fig. 4**

712 **Fig. 4. Unrecognized cyclic pattern of thrombosis onset after travel (8).**

713 **a**, A bar graph showing the relationship between weeks after travel and the number of thrombosis onset in a  
714 figure reported by Cannegieter et al. (8). **b**, Re-expressing as a two-dimensional bar graph avoiding the three-  
715 dimensional representation. **c**, Applying a damped wave by non-linear regression analysis. **d**, Extraction of  
716 damped wave part by subtracting the monotonic decrease function. **e**, Dividing into 2 sub-parts areas by the  
717 envelopes of the damped wave that touch the lower parts of the wave. **f**, Enlarged and added explanation of the  
718 ratio of the area. Cannegieter et al. (8) used the data up to week eight. The ratio of sub-parts 2 to the total number  
719 of patients (ratio of S2 to the area of S1 + S2) was 30.0%. In the integration for the infinite interval, it was  
720 30.8%. Peak shifts of the wave (peak position of the wave shifted from the original to the other) appeared when

721 comparing panels d and f due to putting by regression curve located in the center (c + d). Panel a was re-used  
722 from Cannegieter et al. PLoS Med. 2006; 3(8):e307. Figure 1.

723 <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC1551914/figure/pmed-0030307-g001/> Copyright © 2006  
724 Cannegieter et al. Creative Commons Attribution License. In 2006, the Creative Commons Attribution 2.0  
725 Generic, License (CC BY 2.0) was available. <https://creativecommons.org/licenses/by/2.0/>

726

## 727 **Fig. 5**

728 **Fig. 5. Cyclic pattern of thrombosis onset appeared in a figure by Kelman et al. (9).**

729 **a**, A thrombosis onset distribution reported by Kelman et al. (9). **b**, The regression curve is located in the center  
730 of all average points (the points express the average of thrombosis onset during seven days). **c**, Curve fitting to  
731 the residual data of the regression curve in panel b. **d**, Application of damped wave function and adding  
732 interpretation of the results assuming some women started taking oral contraceptives (OC) in the timing of  
733 travel. The observed cyclic pattern was relatively unclear than Cannegieter et al.(8) (see Fig. 4). Noteworthy, the  
734 thrombosis onset downed in the days before 90 days, and it seems to be the scheduled withdrawal period of OC  
735 use. This figure was re-used and re-drawn from Kelman et al. BMJ. 2003; 327(7423):1072. Figure 1  
736 <https://www.bmj.com/content/327/7423/1072#F1> Copyright © 2003 BMJ Publishing Group Ltd. All rights  
737 reserved. The BMJ permission team thankfully confirms this figure adaptation. Also, we obtained permission to  
738 re-use.

739

## 740 **Fig. 6**

741 **Fig. 6. Hyperbolic shapes found in the figure reported by Matsushita et al. (41).**

742 **a**, A figure reported by Matsushita et al. shows the relationship between the severe and non-severe groups (41),  
743 which shows age difference on the horizontal axis and odds ratio (OR) or hazard ratio of hypertension on the  
744 vertical axis. To evaluate potential confounding for relative risk by age, Matsushita et al. conducted meta-  
745 regression analyses based on the assumption that there was the possibility of confounding by age in the case that  
746 the study with a larger age difference has a higher relative risk (41). **b**, Diabetes. **c**, Cardiovascular disease  
747 (CVD). **d-f**, Comparisons of error bars, which show 95% confidence interval (C.I.) s. It corresponds to the upper  
748 figure. **g-i**, Hyperbolic patterns were fitted to the OR and the 95% confidence limit of the OR. In the panel i, a  
749 hyperbolic shape could not be fitted due to the considerable data variation, likely due to the inconsistency of the  
750 term “CVD” (see **Supporting information: Method details**). The numbers marked at each point are the same as

751 the numbers shown in the original figure. The sources of each data are shown in Methods. This figure was re-  
752 used from Matsushita et al. Glob Heart. 2020; 15(1):64. Figure 5.

753 <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7546112/figure/F5/>

754 Copyright © 2020 The Authors. Creative Commons Attribution 4.0 International License (CC-BY 4.0)

755 <https://creativecommons.org/licenses/by/4.0/>

756

757 **Fig. 7**

758 **Fig. 7. Parabola shape patterns in the figure reported by Guo et al. (10).**

759 **a**, Relationship between high sensitive C-reactive protein (hsCRP) and cardiac troponin T (TnT) in COVID-19  
760 patients (left) and the relationship between cardiac troponin T (TnT) and N-terminal pro-brain natriuretic peptide  
761 (NT-proBNP) (right). **b**, Data points from the right side of panel a and fitting parabola. **c**, Three-dimensional  
762 data visualization was constructed by mounting the value of hsCRP onto panel b. **d**, Linear regression analysis  
763 on the side surface of the parabolic cylinder in panel c. The points were replaced with their average if the values  
764 could not be determined due to overlapping (the points indicated by the left-pointing arrow and the error bar,  
765 which are the average and the range of values, respectively). Panel a was re-used from Guo T et al. JAMA  
766 Cardiol. 2020; 5(7):811-818. Figure 1

767 <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7101506/figure/hoi200026f1/>

768 Copyright © 2020 Guo T et al. JAMA Cardiology. Creative Commons Attribution License (CC-BY).

769 <https://creativecommons.org/licenses/by/4.0/>

770



### Calculation of Odds Ratio & Confidence Interval

**a**

Exposure	Case	Control	Total
Yes	a	b	a+b
No	c	d	c+d
Total	a+c	b+d	a+b+c+d

**b**


$$\text{Odds Ratio (OR)} = \frac{a \times d}{b \times c} = \frac{a/c}{b/d} = \frac{a/b}{c/d}$$

$$95\%CI = \exp \left\{ \log_e(OR) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \right\}$$

$$\log_e(95\%CI) = \log_e(OR) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}}$$

$$\approx \log_e(OR) \pm 1.96 \times \frac{1}{\sqrt{N}}$$

### Numerical Experiment by Using of Binomial Data



### Definition of the Diagram that Should Be Identified in the Figure of Meta-regression Analysis

**d**

$g_1(x) = \left[ \frac{K_1}{1 + \exp\{-L(x-M)\}} + K_2 \right] + (ax^2 + bx + c)$  S + U curve

$f(x) = \frac{K_1}{1 + \exp\{-L(x-M)\}} + K_2$  Sigmoid Function S curve

$g_2(x) = \left[ \frac{K_1}{1 + \exp\{-L(x-M)\}} + K_2 \right] - (ax^2 + bx + c)$  S - U curve

Formula for the Curve of Distribution

$$\frac{df(x)}{dx} = \frac{K_1 L \exp\{-L(x-M)\}}{[\exp\{-L(x-M)\} + 1]^2}$$

Completing the square of the quadratic function

$$ax^2 + bx + c = a \left( x + \frac{b}{2a} \right)^2 - \frac{b^2 - 4ac}{4a}, \quad M = -\frac{b}{2a}$$

Latent distribution that generate target diagram (M: Mean)




**Ideas: Research Concept & Proposed Know-how**  
 Medical data analysis by geometrical viewpoint & explore hyperbolic shape

**Analysis 1** **Traveler's Thrombosis (Economy Class Syndrome)**

**Analysis 1A Dataset : Chandra et al. (2009)**  
**Result : 2 Sub-group Patterns (> 10 h and < 10 h)**  
 Other Findings:  
 • Cannegieter et al.,  
 → Cyclic pattern after travel


4 studies  
 Dataset from Chandra et al.



For reg. analysis  
 2 study data  
 Kuipers et al.  
 Parkin et al.

**Analysis 1B Dataset: Philbrick et al. (2007)**  
**Result : 2 Sub-group Patterns (> 10 h and < 10 h)**  
 Other Findings:  
 • Kelman et al. 2003  
 → Cyclic pattern after travel  
 • Clérel et al., 1999  
 → Periodic pattern in the travel  
 → Association between thrombosis and HRT

10 studies  
 Dataset from Philbrick et al.




For reg. analysis  
 7 study data

**Analysis 2** **COVID-19**

**Analysis 2 Dataset: Matsushita et al. (2020)**  
**Result: 2 Sub-group patterns those which equal to patterns of data cut off days**  
 Other Findings:  
 • Guo et al., 2020 contained 3 sub-group patterns

25 studies  
 Dataset from web figure 5




For reg. analysis  
 6 study data


**Conclusions**  
 "Geometrical approach to bio-medical data" & "explore hyperbolic shape in a figure of meta-regression analysis" are effective for medical research.



### a Source Data Review & Re-draw







### b Explore Latent Hyperbolic Patterns (OR + LN(CI))




























**a**




**d**



**b**

Re-analysis Guo et al. 2020 (Fig. 1B)



**c**

3D Data Visualization on the Plane of Guo et al. Fig. 1B (Sub-group 3)

